BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE. PILANI

HYDERABAD CAMPUS

**FIRST SEMESTER 2019-2020**

**Course Handout (Part-II)**

Date: 01/08/2019

In addition to part I (General Handout for all courses appended to the timetable) this portion gives further specific details regarding the course.

Course No : **PHA G542**

Course Title : Advanced Physical Pharmaceutics

Instructor-in-charge : **V V Vamsi Krishna**

Instructor : L S Lokesh Janardhanam, Deepanjan Datta

**1. Course Description:**

Physico-chemical principles involved in effective formulation development, including various aspects like, crystallinity, particle size, solubility, pKa and stability; development and validation of analytical method, principles and kinetics of dissolution, polymer science, etc.

###### **2. Scope and objective of the course:**

Prior to the development of any dosage form with a new or old drug candidate, it is essential that certain fundamental physical and chemical properties of the drug molecule and other derived properties of the drug are determined. This information dictates possible approaches in formulation development. The aim of this course is to make the students understand those physicochemical principles which must be applied in the formulation and development of an efficacious dosage form, so that required duration and intensity of effect can be ensured at the intended site of action.

1. **Learning outcomes:**

* The student should be able to understand the importance of preformulation characterization of pharmaceuticals and its role in formulation development
* The student should be able understand crystallinity and polymorphism and its importance in formulation development
* The student should be able to apply solubility enhancement strategies
* The student should be able to perform stability studies in accordance with ICH guidelines and understand the outcomes
* The student should be able to understand and correlate utilization of different polymers in formulation development
* The student should be able to calculate the drug release parameters and correlate to physico-chemical properties

1. **Text Book (TB):**

**TB:** Carstensen, J.T. Pharmaceutical Preformulation CRC Press, 1998

1. **Reference Books (R):**

**R1:** Carstensen, J. T., Rhodes, C.T., 2000. Drug Stability: Principles and Practices, Drugs and Pharm. Sci. Series, Vol. 43, 3rd edn, Marcel Dekker Inc., New York.

**R2:** Martin’s Physical Pharmacy and Pharmaceutical Sciences,

1. **Course Plan:**

|  |  |  |  |
| --- | --- | --- | --- |
| **Number of sessions** | Learning Objectives | Topic to be covered | Chapter in Textbook |
| 1 | Stages of drug development, significance of physical pharmaceutics in formulation development | Introduction to physical pharmaceutics | Class notes |
| 2 | Overview of preformulation studies carried out during/ prior to formulation development | Pharmaceutical preformulation | Class notes  Chapter 1, TB |
| 3-10 | Study and impact of crystallinity/ polymorphism, hydrates and solvates on dosage forms | Solid state pharmaceutics | Chapter 7, TB |
| 11, 12 | Techniques of aqueous solubility determination of non-ionized, ionized and unstable drugs | Solubility | Chapter 2, TB; Chapter 9, R2 |
| 13-16 | Impact of pH, ionic strength, surfactants, partition coefficients, dielectric constant, and mixed solvent systems on solubility; Enhancement of solubility | Factors/ parameters affecting solubility | Chapter 2, TB; Chapter 9, R2 |
| 17, 18 | Characterization of powders, microparticles and nanoparticles | Particle size | Chapter 11, TB;  Chapter 18, R2 |
| 19-22 | Various types and sources of stability problems; procedure/ protocol to perform stability studies of drug substances; compatibility studies; characterization of stability; Stability indicating analytical method development | Drug and formulation stability | Chapter 2, R1; Chapter 14, R2 |
| 23-26 | Kinetics of chemical degradation and influence of temperature on degradation | Kinetics of drug stability | Chapter 14, R2 |
| 27-30 | Overview of chemical and physical protein degradation and useful analytical methods for detecting the same | Stability of polypeptides and proteins | Class notes |
| 31-33 | Principles and applications of adsorption; Factors affecting surface tension and critical micelle concentration; Pharmaceutical applications of surfactants | Surface phenomenon | Chapter 9, TB; Chapter 15, R2 |
| 34-36 | Polymer classification, synthesis and characterization. Polymers in dosage forms and drug delivery | Polymers | Chapter 20, R2 |
| 37-40 | Diffusion and dissolution-controlled release process and their mathematical treatment | Principles of diffusion and dissolution | Chapter 10, TB; Chapter 13, R2 |
| 41 | Modeling of drug release kinetics | Release characterization | Class notes |

1. **Evaluation Scheme:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Components** | **Duration** | **Weightage** | **Date and Time** | **Nature of component** |
| Mid-semester test | 90 minutes | 25% | 28/09/2019;  10.00 – 11.30 AM | Closed Book |
| Lab work/  Seminar/ Assignments | Continuous | Weekly lab work 15%  Lab quiz 5%  Lab viva 5%  Seminar 10%  Assignment 5% | continuous | Open book except for lab quiz |
| Comprehensive Examination | 180 minutes | 35% | 02/12/2019 AN | Closed Book (15%)/  Open Book (20%) |

1. **Mid-Semester Evaluation:** Will be announced after mid-semester test
2. **Make-up:** Prior approval or intimation to take a make-up is a must. It is solely the discretion of the instructor-in-charge dependent upon the genuineness of the circumstances to allow a student to appear for a make-up evaluation component.
3. **Grading policy:** As specified in Handout – Part I, appended to the timetable, the instructor in-charge reserves the right to award a NC report in case the student does not make himself/ herself available for any of the evaluation component mentioned above. Also it is not imperative on part of the instructor in-charge to award all the grades. Borderline cases during grading will be judged on the basis of regularity to classes and consistency or progress in the performance in evaluation components. The maximum pull-up to be exercised by the instructor in-charge will be announced in the class and shall be based on the subjective judgment of the evaluator.
4. **Chamber Consultation Hours:** To be announced in the class.
5. **Notices**:Notices concerning the course will be displayed in the Pharmacy Group notice board only.

**Academic Honesty and Integrity Policy**: Academic honesty and integrity are to be maintained by all the students throughout the semester and no type of academic dishonesty is acceptable.

**Instructor-in-charge**

**PHA G542**